RELEASE: Setting The Record Straight — New Fact Check Exposes Big Pharma’s Lies About Medicare Negotiation
Patients For Affordable Drugs Responds To The Industry’s $18 Million Attack Ads Aimed At Thwarting Reforms To Lower Drug Prices
STATEMENT: P4AD Applauds FDA’s Approval Of First Interchangeable Biosimilar Insulin, Calls For Affordable Insulin For All
The FDA’s approval of Semglee as an interchangeable biosimilar to Lantus is an important step forward on the road to real competition.
NEW ANALYSIS: Drug Companies Continue To Hike Prices At Will; Congress Must Act
Patients For Affordable Drugs’ Analysis Highlights Need For Medicare Negotiation For All Drugs
TODAY: Patient, P4AD Founder David Mitchell Tells Senate Judiciary Subcommittee That Anticompetitive Pharma Industry Practices Stifle Innovation, Drive Up Prices
Mitchell Urges Congress To Pass Bipartisan Solutions To Address Anticompetitive Behavior And To Allow Medicare To Negotiate Lower Drug Prices
STATEMENT: Patients For Affordable Drugs Supports Alzheimer’s Association’s Denunciation Of Aduhelm’s Price Set By Biogen
"We stand with the Alzheimer’s Association in its denunciation of the price set by Biogen for the drug Aduhelm."
STATEMENT: Aducanumab FDA Approval And Biogen’s Pricing Prove Urgent Need For Medicare Negotiation
“Today, we are watching our drug pricing system break under the weight of Medicare’s inability to negotiate lower drug prices."
